logo
Beijing keeps up rare earths pressure on Trump

Beijing keeps up rare earths pressure on Trump

Telegraph4 days ago
China is restricting the export of critical minerals to the US as it seeks to maintain pressure on the White House ahead of trade talks this week.
Despite Donald Trump striking a deal with Beijing to resume rare earths imports last month, new figures show that China has restored trade at a far slower pace than with Europe and the rest of Asia.
China exported 3,188 tonnes of rare earth magnets worldwide in June, representing a 158pc jump from May. Of that total, 353 tonnes went to the US, an almost sevenfold increase from the previous month's low of 46 tonnes.
But the average monthly shipment to the US in the first three months of this year was 622 tonnes, suggesting trade is barely back to half the typical level.
The June tonnage was also still 52pc below the amount shipped to the US in the same month last year, representing the largest year-on-year decline of any of China's major magnet customers.
Germany, the largest buyer, received 764 tonnes, up almost threefold from May and down just 25pc year-on-year.
Poland, France, Hungary and South Korea also received large boosts to shipments, and had lower year-on-year declines than the US.
'While China's relationship with the US seems to be warming, Beijing will continue to keep a tight grip on critical mineral exports,' said Leah Fahy of Capital Economics.
China dominates the production and processing of rare earths, and controls most of the world's supply of rare-earth magnets used in military weapons, renewable energy generation and electric vehicles.
When Mr Trump threatened China with wide-ranging tariffs of up to 145pc earlier this year, Beijing responded by halting rare earths exports.
This led to the President quickly caving in amid criticism from American manufacturers. He said on June 11 that he would slash tariffs to restore full access to rare earths.
Meanwhile, Chinese vice-premier He Lifeng will meet US Treasury Secretary Scott Bessent on Monday for two days of trade talks in Stockholm.
Mr Bessent has described the two superpowers' trading relationship as 'in a good place', with reports emerging late on Sunday that they have agreed to extend their truce on tariffs by another 90 days. It had been expected to expire on August 12.
Ahead of the talks, Mr Bessent has said he wants to address China's purchases of Russian and Iranian oil.
Mr Trump has threatened 100pc tariffs on countries that buy Russian oil.
If this levy were imposed on China, by far the biggest buyer, it could reignite the trans-Pacific trade war, and risk jeopardising rare-earth trade once again.
Ms Lahy said China's rare-earth powers might diminish over time.
'There's only so many times China can go back and forth, using it as a way to get things out of the US, without annoying the US even more,' she said.
'And even if China starts supplying as many rare earths as it did before, the genie is out of the bottle. The West knows that China can limit its exports of these goods whenever, so they're going to look to diversify their supply chains.'
Mr Bessent also wants to confront Mr He in Stockholm about what he said was 'overcapacity' at Chinese factories.
The US Treasury has criticised Beijing for lavishing subsidies on its manufacturing industry.
By skewing the Chinese economy towards production and exports ahead of consumption, this helps fuel China's hefty trade surplus with the US – which Mr Trump loathes.
Beijing is taking steps to address this.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

35% tariff on Canada still in the cards, Lutnick says
35% tariff on Canada still in the cards, Lutnick says

Reuters

time25 minutes ago

  • Reuters

35% tariff on Canada still in the cards, Lutnick says

WASHINGTON, July 31 (Reuters) - U.S. Commerce Secretary Howard Lutnick said on Thursday that a 35% tariff on all Canadian goods not covered by the U.S.-Mexico-Canada trade agreement is still "surely in the cards," ahead of an Aug. 1 deadline imposed by President Donald Trump. Lutnick said in an interview on Fox Business Network's "Kudlow" that Canadian Prime Minister Mark Carney could still convince Trump to back down. "If he makes that call, and if he starts turning on the charm, and if he takes off his retaliation ... and stops the silliness, maybe the president will let it down a bit," Lutnick said. "But right now, 35%, that letter he sent, is surely in the cards." Trump sent a letter to Carney in July saying the U.S. would impose a 35% tariff on Canadian goods as of Aug. 1. The two sides have been working on negotiating a trade deal by that deadline, but Trump said last week they may not be able to reach a negotiated deal, suggesting the unilateral tariff rate could be imposed. Earlier this week, Carney said talks were at an intense phase, while reiterating that a deal that would remove all U.S. tariffs was unlikely.

Trump threatens NHS with higher drug prices
Trump threatens NHS with higher drug prices

Telegraph

time27 minutes ago

  • Telegraph

Trump threatens NHS with higher drug prices

Donald Trump is pressuring the world's biggest drug makers to raise prices outside of the US in a threat to the NHS. The US president has written to pharmaceutical companies including Britain's GSK and AstraZeneca to demand they lower prices for Americans, suggesting they should pay for it by charging higher fees abroad. It raises the threat of higher costs for the NHS, which is one of the biggest buyers of pharmaceuticals in the world. In the letters sent to the bosses of 17 pharmaceutical companies, Mr Trump demanded that they 'negotiate harder with foreign freeloading nations' and said that 'increased revenues abroad must be repatriated to lower drug prices for American patients and taxpayers'. He also demanded a 'binding commitment' to these goals and declared that 'other nations have been freeloading on US innovation for too long'. Mr Trump made clear that he would use tariffs to push through higher prices if countries resisted. The White House said the president was prepared to use 'trade policy to support manufacturers in raising prices internationally provided that increased revenues abroad are reinvested directly into lowering prices for American patients and taxpayers.' Drug companies have been set a 60-day deadline to 'step up' and meet the president's demands. He has also called for a commitment that companies 'will not offer other developed nations better prices for new drugs than prices offered in the United States.' Trung Huynh, the head of pharma analysis at UBS, said it was clear Mr Trump wanted companies to charge higher prices in the UK and Europe. Alex Schriver of US drug industry body PhRMA said: 'To reduce price differentials with other countries, policymakers should rein in health care middlemen driving up costs for Americans and get foreign countries to pay their fair share for innovative medicines.' Mr Trump has already targeted NHS drug prices as part of his tariff policy. Last month the Telegraph reported that the White House expected the NHS to pay higher prices for American drugs in an attempt to boost the interests of US corporates. Documents released after the US-UK trade agreement was signed earlier this year said the NHS would review drug pricing to take into account the 'concerns of the president'. Thursday's letter was sent to drug companies including Eli Lilly, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer and Sanofi. Share prices slumped after Mr Trump published his letters on his Truth Social account. AstraZeneca and GSK both fell by more than 4pc, while Pfizer was down by more than 2pc. Mr Trump has long expressed rage about the fact that drug companies make between half and 70pc of their profits in the US despite the country accounting for only a fifth of global sales. Drug prices outside of the US can be as little as 30pc of what Americans pay. Profits from the US are used to fund drug research and development that the rest of the world benefits from. Mr Trump has claimed that US citizens effectively pay for foreign healthcare systems through higher drug prices. He said in 2020: 'In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidising socialism aboard [abroad] with skyrocketing prices at home. 'So we would spend tremendous amounts of money in order to provide inexpensive drugs to another country.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store